- Research Services
- Antibody Discovery
- Antibody and Protein Engineering
- Cell Line Development
- Development & Manufacturing
- Investor Relations
- Contact Us
Antibody and Protein Engineering
Our protein and antibody engineering technologies, Composite Proteins™ and Composite Human Antibodies™, combine the best attributes of deimmunisation and humanization techniques to minimise the immunogenic potential of biopharmaceutical product candidates before they enter clinical development. An immune response can lead to the development of anti-drug antibodies (ADAs) which can reduce efficacy, through the rapid clearance or neutralization of the protein or antibody, and potentially cause toxicity by cross-reacting with other proteins in the body.
Abzena’s Composite Human Antibodies™ and Composite Proteins™ are designed to be devoid of the T cell epitopes that lead to an adverse immune response while minimising the loss of antibody affinity or protein activity that can occur with standard protein engineering techniques.
Once a lead humanized antibody or deimmunised protein candidate has been identified, EpiScreen™ immunogenicity assessment technology is used to confirm T cell epitopes have been removed. We can provide small quantities of antibody or protein for research purposes using either transient expression systems or by generating research-grade stable cell lines. For larger quantities a stable high-expressing manufacturing cell line can be established using our cell line development service and then, if required, this can be transferred to our cGMP manufacturing site or other contract manufacturer.
Abzena’s antibody engineering technology is used to generate humanized and fully functional antibodies devoid of T cell epitopes in the variable region sequences to reduce immunogenicity in patients.
Abzena’s protein engineering technology is used to generate deimmunised therapeutic proteins devoid of human T cell epitopes to minimise potential immunogenicity in patients without compromising protein activity.
Affinity maturation using phage or mammalian display is provided to improve the binding affinity of an antibody for its target antigen by random and oligonucleotide directed mutation without impacting specificity. Specific antibody selection methods can be incorporated into the process to reduce the risk of immunogenicity in patients.
Bioassays and Bioanalytics
Abzena’s bioassay services are designed to be there at any point in drug development pathway helping clients with support for specific biological assay development.
Working with Abzena
Abzena’s services are tailored for each project to ensure that the objectives are met or exceeded. Experienced project teams are assigned to each study focusing on progressing projects through to results in the minimum amount of time. Our clients widely regard us as professional and attentive partners who deliver quality results.
To get more information, a quote or to schedule a teleconference please contact us.